Tips for the Time-Starved Oncologist, CLL Remission, Olaparib StudyNovember 09, 2020 | Oncology Allergy & Immunology 7 Time-Saving Tips for Doctors We all have the same number of hours in the day. Things need to get done, and when you’re a physician, sometimes the day is gone before you feel like you even got started. Here are some tips and tricks to help streamline your schedule and improve your time management. You, your staff, and your family will appreciate the productivity and efficiency gains these tips could offer. Read full article Hematology Three-Drug Combination Induces Deep Remission in Treatment-Naive, R/R CLL Are traditional cytotoxic chemotherapies becoming a thing of the past? This study in the Journal of Clinical Oncology shows a move toward targeted agents, as a combination of obinutuzumab, ibrutinib, and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Read full article Hematology TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes Olaparib, a PARP inhibitor, is approved for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) in germline (g)BRCA1/2 mutation carriers. Find out whether the results from this latest report will emphasize the value of molecular characterization (homologous recombination (HR)–related genes other than BRCA1/2) for treatment decisions in MBC. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS